Your browser doesn't support javascript.
loading
The Role of RNA-Binding Proteins in Hematological Malignancies.
Aguilar-Garrido, Pedro; Otero-Sobrino, Álvaro; Navarro-Aguadero, Miguel Ángel; Velasco-Estévez, María; Gallardo, Miguel.
Afiliação
  • Aguilar-Garrido P; H12O-CNIO Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain.
  • Otero-Sobrino Á; Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Navarro-Aguadero MÁ; H12O-CNIO Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain.
  • Velasco-Estévez M; Department of Hematology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain.
  • Gallardo M; H12O-CNIO Hematological Malignancies Clinical Research Unit, CNIO, 28029 Madrid, Spain.
Int J Mol Sci ; 23(17)2022 Aug 23.
Article em En | MEDLINE | ID: mdl-36076951
ABSTRACT
Hematological malignancies comprise a plethora of different neoplasms, such as leukemia, lymphoma, and myeloma, plus a myriad of dysplasia, such as myelodysplastic syndromes or anemias. Despite all the advances in patient care and the development of new therapies, some of these malignancies remain incurable, mainly due to resistance and refractoriness to treatment. Therefore, there is an unmet clinical need to identify new biomarkers and potential therapeutic targets that play a role in treatment resistance and contribute to the poor outcomes of these tumors. RNA-binding proteins (RBPs) are a diverse class of proteins that interact with transcripts and noncoding RNAs and are involved in every step of the post-transcriptional processing of transcripts. Dysregulation of RBPs has been associated with the development of hematological malignancies, making them potential valuable biomarkers and potential therapeutic targets. Although a number of dysregulated RBPs have been identified in hematological malignancies, there is a critical need to understand the biology underlying their contribution to pathology, such as the spatiotemporal context and molecular mechanisms involved. In this review, we emphasize the importance of deciphering the regulatory mechanisms of RBPs to pinpoint novel therapeutic targets that could drive or contribute to hematological malignancy biology.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Neoplasias Hematológicas / Linfoma Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia / Neoplasias Hematológicas / Linfoma Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article